Monday, May 7, 2012

Novartis builds further evidence on Lucentis superior profile over Avastin

Novartis has announced interim results from the IVAN study (Inhibit VEGF in Age Related choroidal macular Neovascularization) which showed that Avastin failed to match Lucentis in vision gains at year one. This data in conjunction with two year safety data from CATT study  should put pressure on ophthalmologists using Avastin as an off-label treatment in AMD.
 The new IVAN data also supports that Lucentis when administered as needed is as effective as monthly therapy.